With the technical assistance of Jack D. Frank LY210825, a recombinant tissue-type plasminogen activator (rt-PA), which contains the kringle-2 and serine protease functional domains of native tissue-type plasminogen activator, was previously produced by site-directed mutagenesis in a Syrian hamster cell line. We studied the thrombolytic potential of this molecule in a canine thrombosis model. Male hounds (16-22 kg) were anesthetized; a 2.0-cm segment of the left circumflex coronary artery (LCX) was isolated proximal to the first main branch, and the dogs were instrumented with an electromagnetic flow probe to measure coronary blood flow. An occlusive thrombus was formed after injury of the intimal surface of the LCX with an electrical current applied by a needle-tipped anode placed distal to the electromagnetic flow probe. After 1 hour of occlusion, either LY210825 or rt-PA was administered intravenously according to the following protocols: 1) a 1-hour infusion of either 0.25 mg/kg LY210825 or 0.4 mg/kg rt-PA, 2) single injections of 0.15-0.6 mg/kg LY210825, and 3) a single injection of 0.45 mg/kg LY210825 and a 3-hour infusion of 1.0 or 1.7 mg/kg rt-PA. Plasma half-lives of LY210825 and rt-PA were 58±7 and 3.3+±0.3 minutes, respectively. LY210825 produced more rapid reperfusion of the LCX than did rt-PA. In the third study, 90% of the rt-PA-treated vessels reoccluded within 1 hour after cessation of drug, whereas only 25% of the LY210825-treated vessels reoccluded during a 4-hour washout period. There were significant, but relatively small, reductions produced by both plasminogen activators on plasma fibrinogen and plasminogen (25-35% decreases). Because of its longer plasma half-life, LY210825 could be administered intravenously as a single injection. In a canine model of coronary artery thrombosis, LY210825 was a more effective thrombolytic agent than was rt-PA. (Circulation 1990;82:930-940) Since the approval of streptokinase and recombinant tissue-type plasminogen activator (rtc PA) for intravenous administration in acute myocardial infarction, there has been significant growth in the acceptance of thrombolytic therapy for
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There is a sparsity of data describing the thrombolytic efficacy of variant plasminogen activators in animals. Lau et al1l' have described a variant that contains an asparagine to glutamine point mutation that prevents N-glycosylation at residue 451 of the native t-PA molecule. This variant demonstrated a biphasic clearance with component half-lives in the rabbit of 0.9 minutes and 27 minutes compared with a monophasic 3-minute half-life for t-PA. Thrombolysis in a rabbit venous thrombosis model was not different from that observed with native t-PA. Larsen et al'2 described a deletion variant that had the finger region epidermal growth factor region, and glycosylation at three sites removed (t-PA-AFE3X). This molecule was thrombolytic in a rabbit model of venous thrombosis13 and in a canine model of copper coil-induced coronary artery thrombosis. ' 
Hematologic and Coagulation Assays
Whole blood cell counts and analyses of hemoglobin and hematocrit levels were determined with a 40-gl citrated blood sample processed with a hematology analyzer (Cell-Dyn 900, Sequoia-Turner, Mountain View, Calif.). Duplicate blood samples (3.8% citrate and 3.8% citrate+trasylol, 500 KIU/ml) were drawn for determining plasma plasminogen, a2-antiplasmin (citrated samples) and fibrinogen, and plasminogen activator antigen and functional activity concentrations (citrate+trasylol samples). Trasylol was added to prevent in vitro fibrinogenolysis. Fibrinogen level was determined in plasma by a thrombin clotting time assay20 which involved the addition of 100 gl bovine thrombin (10 NIH units/ml) to 200 ,ul diluted dog plasma (0.1 ml plasma diluted with 0.9 ml 3% bovine serum albumin). Clotting times were recorded with a Fibrometer (BBL) or a CoA Screener (American LABor Co., Largo, Fla.) Standard curves were constructed with purified dog fibrinogen in 3% bovine serum albumin for absolute estimations of fibrinogen or from serial dilutions of the prestimulation (predrug) plasma sample for relative changes in plasma fibrinogen concentrations. Plasminogen level was determined by the chromogenic procedure that uses excess streptokinase to activate the plasma.2122 a2-Antiplasmin was determined by a chromogenic assay where known amounts of plasmin were added to the test plasma to measure enzyme inhibition capacity of the sample.23 Plasminogen and a2-antiplasmin assays were performed immediately after the plasma samples were prepared.
Plasminogen Activator Antigen and Functional Enzyme Activity Assays A polyclonal antibody was used to immunologically capture plasminogen activator molecules for concurrent antigen and plasminogen activator activity determinations. Antigen concentrations were determined with a modification of a t-PA enzyme-linked immunosorbent assay (American Diagnostica, Greenwich, Conn. Antigen Assay. EIA (enzyme-immunoassay) plates were coated overnight with 200 ,l polyclonal antit-PA antibody (8.8 ,ug/ml). After washing the plates four times with PET buffer, 200 gl nonspecific goat IgG (8.8 ,gg/ml) was added to the wells. Plasma samples were added to designated wells (10 ,ul plasma appropriately diluted with 3% bovine serum albumin in saline), and the plates were allowed to stand at room temperature for 3 hours. The plates were then washed four times with PET buffer, and 200 ,ul OPD/H202 (0.042/0.04% in H20) was added to each well and allowed to stand at room temperature for 30 minutes in the dark, at which time 50 gl 3N H2S04 was added to stop the horseradish peroxidase reaction. Optical density values (at 490 nm) were determined with a Vmax plate reader (Molecular Devices, Palo Alto, Calif.). Data were analyzed by use of a nine-point standard curve with appropriate reference t-PA concentrations from the same EIA plate. All data were subjected to a curve-fitting program (SOFTmax, Molecular Devices) so that correlation coefficients were greater than 0.97. Standard deviations among the unknowns were 10% or less. The useful range of sample concentrations as applied in 10-pl amounts in this system was 1.0-40.0 ng/ml in the diluted sample or reference standard.
Functional activity of immunologically captured antigen. To measure the plasminogen activating activity of the antigen captured in the antigen assay procedure (above), a second EIA plate was prepared as above and treated exactly the same except this second plate was treated with plasminogen and S-2251 Drugs and Data Analysis LY210825 was expressed, purified, and characterized as described by Burck et al. 17 Briefly, LY210825 was expressed in an adenovirus-transformed Syrian hamster cell line, grown in suspension culture, and purified from culture medium with affinity chromatography. LY210825 has the following characteristics: 358 amino acids make up the kringle-2 and seine protease functional domains of native t-PA, had more than 95% single-chain content, and had a fibrinolytic specific activity=0.9-1.2x106 IU/mg. The t-PA used for comparison in this study was recombinant, had more than 95% single-chain material, and had a fibrinolytic specific activity = 580,000 IU/mg (rt-PA, Activase, Genentech, South San Francisco, Calif.).
Animals were rejected if 1) their vessels were totally occluded before 45 minutes or had not occluded by 90 minutes from initiation of electrolysis, 2) their whole blood platelet count was 150,000/,lg or less, and 3) they required more than three internal defibrillation countershocks (30- Data comparisons between LY210825-and rt-PAtreated groups were performed with single-factor analysis of variance followed by Dunnett's multiple range test to determine the level of significance between groups. A two-factor repeated measures analysis of variance was performed to determine significant differences between different time points during the experiment. Fisher's exact test was used to determine significant differences on the incidence of reocclusion between LY210825 and rt-PA treatments. These animal studies conformed to the guiding principles of the American Physiological Society for the use of animals in research.
Results

One-Hour Infusion Study
A study was performed to assess the thrombolytic potential of LY210825 and determine whether this truncated form of rt-PA possessed a longer plasma half-life compared with rt-PA. All groups demonstrated similar times to occlusion: Vehicle, 71 + 11 minutes (n =5); LY210825, 72+6 minutes (n =4); and rt-PA, 55±12 minutes (n=5, mean+SEM). Table 1 illustrates that a 1-hour infusion of LY210825 (0.25 mg/kg) lysed coronary thrombi and resulted in shorter times to reperfusion than did rt-PA (0.4 mg/kg), 34+3.2 versus 50±5.2 minutes (p<0.01), respectively. The doses of plasminogen activators used were essentially equivalent in the amount of active material infused: LY210825 was 225,000 IU/kg (calculated using a specificity activity of 0.9 x 106 IU/mg material used for this study), and rt-PA was 232,000 IU/kg. After cessation of the drug infusion, patency of the LCX was monitored until the end of the experiment (2 hours). All LY210825 -treated vessels maintained flow until the end of the experiment (i.e., no reocclusion), whereas all of the rt-PAtreated vessels reoccluded within 30 minutes after cessation of drug. LY210825-treated vessels maintained more average flow during the reperfusion period than did corresponding rt-PA-treated vessels (15.1±6.9 versus 2.0+1.4 ml/min, p<0.01), respec- Single Injection of LY210825 Figure 2 illustrates that the longer plasma half-life of LY210825 allows this molecule to be administered as a single injection. Nine dogs received a single injection of LY210825 at doses of 0.15 mg/kg (n=3), 0.3 mg/kg (n=3), and 0.6 mg/kg (n=3). The antigen area under the curve for these doses increased in a linear, dose-dependent manner, whereas the plasma half-lives of the three LY210825 doses were similar (approximately 60 minutes). Thrombolytic efficacy determinations for LY210825 in this study were as follows. 1) Time to reperfusion: 43 (n=2), one did Table 2 demonstrates that baseline (prestimulation) heart rate, mean arterial pressure, and coronary blood flow were similar among all groups. Thrombolytic therapy produced significant decreases in mean arterial pressure at the end of the reperfusion period for LY210825 and rt-PA, probably because of reperfusion arrhythmias and loss of blood (e.g., surgical wounds, blood sampling). Time to occlusion of the LCX was similar among all groups: 70+6, 62+3, and 56±2 minutes for 1.0 and 1.7 mg/kg rt-PA and LY210825, respectively. Significant return and maintenance of coronary blood flow was observed after thrombolysis with LY210825 and rt-PA. After a single injection of LY210825, however, more rapid thrombolysis was observed compared with both doses of rt-PA. Vessels exposed to LY210825 demonstrated a significant earlier time to reperfusion of 17±2 minutes compared with 65±9 and 43±6 minutes for 1.0 and 1.7 mg/kg rt-PA, respectively (Table 3) . When the drug infusion of either 1.0 or 1.7 mg/kg rt-PA was stopped, all but one vessel reoccluded; reocclusion time for 1.0 mg/kg was 18±6 minutes (four of four; two of four vessels had reoccluded before the end of drug infusion), and reocclusion time for 1.7 mg/kg was 51±5 minutes (five of six vessels reoccluded) ( Table 3) . Only two of eight vessels exposed to LY210825 reoccluded within the 4-hour reperfusion and washout period. Figure 4 shows the differences between a single injection of LY210825 and a 3-hour infusion of rt-PA. The average coronary blood flow maintained during the 3-hour reperfusion period was similar for both LY210825 and rt-PA groups; peak coronary blood flow was approximately 20 ml/min immediately after reperfusion. In addition, the LCX vessels from the LY210825 -treated group maintained patency for a significantly longer period of time after cessation of drug administration. Coagulation proteins. Table 5 illustrates that rt-PA and LY210825 caused decreases in circulating a2-antiplasmin and fibrinogen (ranges, 35-51% and 22-35%, respectively). Circulating plasminogen was the least affected; only the high dose of rt-PA demonstrated significant activation of systemic plasminogen. These effects of the plasminogen activators on circulating coagulation proteins were not sufficient to cause profuse bleeding from the surgical wounds. All preparations, however, demonstrated bleeding from surgical sites. Discussion The present investigation describes the thrombolytic potential of a novel t-PA variant, LY210825. This molecule, derived from a Syrian hamster cell line, contains the kringle-2 and serine protease functional domains of native t-PA. LY210825 had a longer plasma half-life compared with rt-PA, produced rapid reperfusion of a coronary thrombus, and prevented reocclusion of the LCX after a single injection of the thrombolytic. The objective of the initial study was to determine the thrombolytic activity of LY210825 compared with rt-PA at equivalent doses of plasminogen activator. LY210825 produced more rapid reperfusion and maintained flow better than did rt-PA, even though circulating peak antigen concentrations for both LY210825 and rt-PA were similar during a 1-hour infusion. One possible reason for the improved efficacy may be because LY210825 demonstrated a 15-20-fold increase in circulating half-life compared with rt-PA (60 minutes versus 3 minutes). The longer half-life would allow for a period of extended thrombolysis. Functional domain or glycosylation changes have been shown to extend circulating half-lives of variant t-PAs in rabbits"1'13'15 and dogs.14 LY210825 has had the finger, EGF, and kringle-1 functional domains removed by site-directed mutagenesis. Kalyan and coworkers27 observed that deletion of the finger and EGF domains of t-PA produced an extension in circulating half-life from 2 to 50 minutes in mice but caused an appreciable decrease in fibrin binding. Similar observations were made by Lucore et al '5 in the rabbit with a variant deficient in the EGF domain (a 25-minute half-life). Therefore, the lack of the EGF domain in LY210825 probably contributed to its longer plasma half-life.
Thrombolytic efficacy in the face of minimal systemic fibrinogenolysis suggests that LY210825 main-FIGURE 4. Plot ofthrombolytic efficacyfor a single injection ofLY210825 and two 3-hour infusions ofrecombinant tissuetype plasminogen activator (rt-PA). First value for coronary blood flow begins at the time of reperfusion (see Table 3 ).
aPrestimulation coronary blood flow. 39 The 7E3 monoclonal platelet GPIIb/ Illa antibody has been shown to be effective in preventing reocclusion after thrombolysis with rt-PA. 40 Fitzgerald et a141 have demonstrated that aspirin and prostacyclin, as well as the 7E3 platelet GPIIb/IIIa antibody, also were effective adjuncts to rt-PA-induced thrombolysis in the canine model. All of these studies included heparin anticoagulation as part of the thrombolytic protocol. Since neither heparin nor any type of adjunct was used in the present study, the ability of a single inijection of LY210825 to not only induce rapid reperfusion but to also prevent reocclusion becomes even more significant.
The single injection of LY210825 provided immediate concentrations of the plasminogen activator that were in the range required for thrombolysis. Because of the longer half-life of LY210825, necessary sustained concentrations of the plasminogen activator were maintained so that the LCX remained patent even after only a single injection. Conversely, even though rt-PA provided timely reperfusion and maintained blood flow during drug infusion, all but one LCX in the rt-PA groups reoccluded as soon as the rt-PA infusion was stopped (Table 3, Figure 4) .
The time at which the six patent vessels in the LY210825 group would have reoccluded could not be determined because of the time limit of the reperfusion and washout phase of the experimental protocol. A single injection of rt-PA administered before the infusion was begun may have decreased the time to reperfusion, but the total dose would have been much greater than 1.7 mg/kg. LY210825 and rt-PA had similar effects on blood pressures, hematocrit levels, and hemoglobin levels (Tables 2 and 4 ). Changes in these parameters observed at the end of the experiments most likely reflect hemoconcentration, blood loss due to indiscriminant lysis of hemostatic plugs by the plasminogen activators as well as volume depletion from blood sampling. There was no effect on platelet count by either plasminogen activator. The plasma proteins, a2-antiplasmin, plasminogen, and fibrinogen were reduced (Table 5) ; however, the reductions were not indicative of significant systemic fibrinogenolysis in response to LY210825 or rt-PA. These data indicate that although LY210825 has a longer plasma half-life than rt-PA, it has the capacity for excellent thrombolytic efficacy without the liability of compromising the systemic coagulation cascade (i.e., potential lower risk of peripheral or cerebral bleeds).
These data demonstrate that the novel recombinant t-PA variant, LY210825, is an effective thrombolytic agent. LY210825 possesses the kringle-2 and serine protease functional domains of native t-PA and, as a result, is fibrin specific and capable of thrombolysis. LY210825 demonstrated a 15-to 20-fold longer plasma half-life than rt-PA. Consequently, a single injection of LY210825 (2.5-to 3-fold lower dose than rt-PA) produced more rapid reperfusion than did a 3-hour infusion of rt-PA and prevented reocclusion without additional pharmacological therapy (e.g., heparin, GPIJb/I11a antibody). LY210825 was as fibrinogen sparing as was rt-PA. This investigation demonstrates that in a canine model of coronary artery thrombosis, LY210825 is a superior thrombolytic agent compared with rt-PA. Because LY210825 can be administered easily and safely as a single injection, this novel thrombolytic may be useful in prehospital settings where physician or trained paramedic emergency care is available.
